Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) – Pipeline Review, H2 2016’, provides in depth analysis on Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) targeted pipeline therapeutics.

The report provides comprehensive information on the Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2)

The report reviews Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) targeted therapeutics and enlists all their major and minor projects

The report assesses Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Cleveland BioLabs, Inc.

Neuropore Therapies, Inc.

Opsona Therapeutics Limited

Vascular Biogenics Ltd.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Overview 7

Therapeutics Development 8

Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Products under Development by Stage of Development 8

Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Products under Development by Therapy Area 9

Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Products under Development by Indication 10

Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Products under Development by Companies 14

Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Products under Development by Universities/Institutes 16

Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Therapeutics Assessment 18

Assessment by Monotherapy/Combination Products 18

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Companies Involved in Therapeutics Development 25

Cleveland BioLabs, Inc. 25

Neuropore Therapies, Inc. 26

Opsona Therapeutics Limited 27

Vascular Biogenics Ltd. 28

Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Drug Profiles 29

CBLB-612 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

CBLB-613 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

DMT-200 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

DMT-210 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

DMT-220 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

infectious vaccine - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

OPN-305 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

P-13 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

P-MAPA - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Small Molecules to Agonize TLR2 for Neurodegenerative Diseases - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Small Molecules to Antagonize TLR-1 and TLR-2 for Infectious Disease and Neuroinflammation - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Small Molecules to Antagonize TLR2 and TLR4 for Immune inflammatory Diseases - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

SP-16 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Synthetic Peptide to Target PPAR-Gamma and TLR-2 and IBD and Tissue Injury - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Vaccine to Target MUC-1 and TLR-2 for Breast Cancer - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

VB-201 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Dormant Projects 51

Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Discontinued Products 54

Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Featured News & Press Releases 55

May 16, 2016: Dermata Therapeutics Announces Initiation of Phase 1 Pharmacokinetic Study 55

Jan 26, 2016: Cleveland BioLabs Announces Start of Phase 2 Study of CBLB612 in Russian Federation 55

Jul 13, 2015: Cleveland BioLabs Announces Results of Phase 1 Study of CBLB612 in Russian Federation 56

Apr 02, 2015: Cleveland BioLabs Announces New U.S. Composition of Matter Patent for CBLB612 56

Mar 16, 2015: Cleveland BioLabs Announces Completion of Dosing in Phase 1 Study of CBLB612 in Russian Federation 57

Mar 02, 2015: Opsona Therapeutics commences Part B of phase II study of Blocking Toll-Like Receptor 2 in Extended Criteria Donor renal transplant recipients at high risk of Early Graft Dysfunction 57

Feb 23, 2015: Opsona Therapeutics Patent issued in USA covering an antibody directed against Toll-like Receptor-2 (TLR-2) and the use and development thereof 57

Feb 18, 2015: Opsona Therapeutics Patent issued in US and EU covering the Opsona-developed antibody OPN-305, which is directed against Toll-like Receptor-2 (TLR-2) and the use and development thereof 58

Feb 17, 2015: VBL Therapeutics Reports Topline Results From Phase 2 Studies of VB-201 in Psoriasis and Ulcerative Colitis 59

Feb 09, 2015: VBL Therapeutics to Present Preclinical Data at Keystone Symposium on Liver Metabolism and Nonalcoholic Fatty Liver Disease 60

Feb 06, 2015: VBL Therapeutics Receives European Patent Issuance on Lecinoxoid Platform Technology 61

Jan 29, 2015: VBL Therapeutic In Cooperation With KCR Reported LPO In Phase 2 Of VB-201 61

Jan 27, 2015: Opsona Therapeutics initiates phase I / II prospective open in patients with myelodysplastic syndrome second line of lower level (low and intermediate-1) with OPN-305 label ... 62

Jan 27, 2015: Opsona Therapeutics OPN-305 examines pretreatment myelodysplasia 62

Jan 26, 2015: Opsona Therapeutics initiates a prospective open label Phase I/II study in second-line lower (Low and intermediate-1) risk myelodysplastic syndrome (MDS) with OPN-305, a First-in Class Monoclonal 62

Appendix 64

Methodology 64

Coverage 64

Secondary Research 64

Primary Research 64

Expert Panel Validation 64

Contact Us 64

Disclaimer 65

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 15

Number of Products under Investigation by Universities/Institutes, H2 2016 16

Products under Investigation by Universities/Institutes, H2 2016 17

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Stage and Mechanism of Action, H2 2016 20

Number of Products by Stage and Route of Administration, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 24

Pipeline by Cleveland BioLabs, Inc., H2 2016 25

Pipeline by Neuropore Therapies, Inc., H2 2016 26

Pipeline by Opsona Therapeutics Limited, H2 2016 27

Pipeline by Vascular Biogenics Ltd., H2 2016 28

Dormant Projects, H2 2016 51

Dormant Projects (Contd..1), H2 2016 52

Dormant Projects (Contd..2), H2 2016 53

Discontinued Products, H2 2016 54

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Mechanism of Actions, H2 2016 19

Number of Products by Stage and Mechanism of Actions, H2 2016 19

Number of Products by Routes of Administration, H2 2016 21

Number of Products by Stage and Routes of Administration, H2 2016 21

Number of Products by Molecule Types, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 23

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared